Migraine Headache - Myth vs Facts

News
Slideshow

There is a good deal of misinformation available about migraine headaches. Which of these 10 statements are myth and which are fact?

  

Recent Videos
Primary Care is the Answer to the Migraine Care Gap, Says Headache Specialist
Migraine Management Pearls for Primary Care with Neurologist Jessica Ailani, MD
Migraine-specific therapies belong in primary care setting, Jessica Ailani, MD
Related Content
Higher Daily Step Count Linked to Lower Risk for Depression: Daily Dose / image credit: ©New Africa/AdobeStock

Higher Daily Step Count Linked to Lower Risk for Depression: Daily Dose

Sydney Jennings
January 15th 2025
Article

Your daily dose of the clinical news you may have missed.

Distress Signals: How to Help a Clinician Colleague in Need

Distress Signals: How to Help a Clinician Colleague in Need

Sydney Jennings
February 14th 2023
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Rebekah Bernard, MD, a family physician and national speaker on physician wellness.

Minimal Distress Reported with Multi-Cancer Early Detection Testing: New Findings from PATHFINDER Trial / Image credit: ©Christoph Burgstedt/AdobeStock

Minimal Distress Reported with Multi-Cancer Early Detection Testing: New Findings from PATHFINDER Trial

Sydney Jennings
January 14th 2025
Article

A new analysis of patient reported outcomes from the PATHFINDER study indicate the potential clinical benefit of early cancer detection.

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

Sydney Jennings
September 29th 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Lynn Webster, MD, past president of the American Academy of Pain Medicine.

New Long-Term Data Suggest Continued Blarcamesine Efficacy in Alzheimer Disease Up to 4 Years / image credit ©Visualmind/stock.adobe.com

New Long-Term Data Suggest Continued Blarcamesine Efficacy in Alzheimer Disease Up to 4 Years

Grace Halsey
January 14th 2025
Article

Blarcamesine significantly slowed progression of both cognitive and functional decline, with treatment initiated earlier in disease process more effective than that initiated later.

Phase 1b Trial of Oligomer-Targeting Agent PMN310 for Alzheimer Disease Gets Underway / Image credit: ©Zerbor/AdobeStock

Phase 1b Trial of Oligomer-Targeting Agent PMN310 for Alzheimer Disease Gets Underway

Sydney Jennings
January 13th 2025
Article

The study will assess the safety, tolerability, and pharmacokinetics of PMN310 in individuals with mild cognitive impairment or early-stage AD.

© 2025 MJH Life Sciences

All rights reserved.